NV
Novozymes A/S
NVZMF · OTC
$65.11 +0.00% (+$0.00)
1M -8.45%
Market Cap 27.0B €
P/E Ratio 42.78x
Div. Yield 1.57%
ROE 5.78%
Bulios Fair Price
$44.06
32.3% downside
Current Price
$65.11
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NVZMF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
17 /100
Expensive P/E 42.78x
P/FCF 49.36x
EV/EBITDA 20.70x
Growth
1 /100
Declining EPS growth 54.41%
Book val. growth 7.77%
Rev. growth 38.13%
Profitability
100 /100
Strong Gross margin 54.85%
FCF margin 12.74%
Net margin 14.70%
Quality
44 /100
Average ROIC 6.24%
Asset turnover 0.26x
ROE 5.78%
Debt
90 /100
Low Debt/Equity 0.28x
Net debt/EBITDA 1.91x
Current ratio 1.74x
Stability
43 /100
Moderate Beta 0.62x
Profitable years 6
Rev. volatility 48.54%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NVZMF
Online
Sector
Basic Materials
Industry
Chemicals - Specialty
CEO
Ester Baiget
Employees
11,641
Headquarters
Lyngby
Upcoming events
05 NOV
Earnings
Upcoming earnings report